



20. MDR-TB: treatment and adverse reactions Thursday, 30 October 2014, 10:15-11:15

Chair: Manfred Danilovits (Estonia)

Section: Tuberculosis

- PD-719-30** **Spectrum of further drug resistance in multidrug-resistant tuberculosis patients from 9 countries in regards to bedaquiline implementation**
E Kurbatova, T Dalton, J Ershova, P Cegielski, and Global Petts Investigators (*USA*)
- PD-720-30** **Analysis of the work of the MDR-TB councilium in a region with a high level of drug resistance and HIV prevalence**
D Ruzanau, A. Khailiaukin, A. Demidova, S. Zhevnyak, N Juravleva, M. Uranova (*Belarus*)
- PD-721-30** **Emergence of fluoroquinolone resistance amongst multidrug-resistant tuberculosis suspects at a tertiary care facility in Karachi**
N Khalid, A Zaidi, N Rizvi, A Haseeb, A Malik, S Khowaja, N Saifullah, A Mohiuddin (*Pakistan*)
- PD-722-30** **Verapamil potentiates the activity of Bedaquiline (BDQ) in the mouse TB model: a strategy to reduce BDQ toxicity**
S Gupta, S Tyagi, K Winglee, M Maiga, W Bishai (*USA*)
- PD-723-30** **Conditions affecting the minimal inhibitory concentration (MIC) of bedaquiline against Mycobacterium tuberculosis**
N Lounis, L Vranckx, T Gevers, K Kaniga, K Andries (*Belgium, USA*)
- PD-724-30** **Trend of fluoroquinolone resistance in Thai new pulmonary tuberculosis patients**
C Chuchottaworn (*Thailand*)
- PD-725-30** **Hypokalaemia and elevation of serum creatinine in patients with rifampicin resistant TB treated with kanamycin and capreomycin in Khayelitsha**
S Moyo, P Patient, V Cox, J Daniels, O Muller, G Van Cutsem, H Cox (*South Africa*)
- PD-726-30** **Quantitative second-line drug susceptibility in patients treated for multidrug-resistant tuberculosis in Bangladesh: implications for regimen choice**
S Heysell, S Ahmed, s Rahman, A Mahmud, E Houpt, S Banu (*USA, Bangladesh*)
- PD-727-30** **What is the prevalance of adverse drug reactions among multidrug-resistant TB patients in a DR-TB centre of India in last four years?**
S Sarkar, T Quazi, Dr. Ashok Sen, Dr. Br Pradhan, dr. Santanu Haldar, B Bishnu, Dr. Nilanjan Paty, Dr. Suparna Chattopadhyay (*India*)
- PD-728-30** **Laboratory monitored drug adverse events in patients undergoing treatment for drug resistant tuberculosis in Khayelitsha, South Africa**
S Moyo, P Patient, V Cox, J Daniels, O Muller, G Van Cutsem, H Cox (*South Africa*)
- PD-729-30** **Prevalence of XDR, ofloxacin- and aminoglycosid-resistance among different MDR tuberculosis cases**
N. Lytvynenko, S. Cherenko (*Ukraine*)
- PD-730-30** **DNA methylation and its role in the resistance of Mycobacterium tuberculosis to levofloxacin**
A Nataly, J Robledo, F Rouzaud (*Colombia*)